Morgan Stanley Resumes Abbvie (ABBV) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Morgan Stanley Resumes Abbvie (ABBV) at Equalweight
May 28, 2015 9:01 AM EDT
AbbVie's (NYSE: ABBV) Pharmacyclics, Inc. announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca (NYE: AZN). The Phase Ib/II study will examine the safety, tolerability and effectiveness of this... More
May 26, 2015 8:33 AM EDT
AbbVie (NYSE: ABBV) has completed the acquisition of Pharmacyclics, Inc. (Nasdaq: PCYC) enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics is a leader in the hematological oncology market with Imbruvica® (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 billion global market.
"The companies' shared expertise, combined with AbbVie's broad late-stage oncology pipeline, has the potential to transform the cancer treatment landscape for hematological malignancies and improve patient outcomes and quality of life," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.... More
